argenx SE Investor Day Presentation Deck
ARGX-117 SAD: Long Half-life and Sustained PD Profile
Mean ARGX117 Concentration µg/ml (log scale)
1 E7-
1E6-
1E5
1E4-
1E3
1 E2-
1 E1-
14+
Beeeee
0
argenx
7
Pharmacokinetics
14 21 28 35 42 49
Conclusions
56
63
70 77
days
Days
84
T
91 98 105 112 119 126 133 140 147
●
●
●
Mean Free C2 µg/ml(log scale)
100
10-
0.1-
0.01-
0 7
Free C2 levels
21 28 35 42 49
56
63
A
Placebo IV/SC
0.1 mg/kg ARGX-117 IV
0.5 mg/kg ARGX-117 IV
2.5 mg/kg ARGX-117 IV
10 mg/kg ARGX-117 IV
70 77
Days
-4
84 91 98 105 112 119
Estimated half-life~ 65-70 days
Dose proportional increase of Cmax
Sustained reduction in free C2 levels by 95% for > 100 days as of 30 mg/kg dose
95%
reduction
99%
reduction
30 mg/kg ARGX-117 IV
60 mg/kg ARGX-117 IV
60 mg/kg ARGX-117 SC
80 mg/kg ARGX-117 IV
126 133 140 147
58View entire presentation